Cantel Medical Corp (CMN) posted yet another earnings surprise with a 65% increase in net income.

Company Description

Cantel makes medical products to prevent and control infections. The products are sold globally and range from water purification to disposable items like masks, wipes, and other products.

Net Income Up 65%

On Oct 9 the company reported fourth-quarter results that included a 65% jump in net income, to $4.3 million. Earnings per share came in at 26 cents, 4 cents higher than the Zacks Consensus Estimate and 10 cents higher than the same period last year.

A 4% rise in sales, to over $64 million, drove earnings higher. Cantel's full-year earnings were up 79% to 94 cents, almost double last year's 53 cents.

Fighting Swine Flu

Cantel sells a mask that is specially treated to fight infections, including seasonal flu and the H1N1 virus. The mask is treated with a special

...

For Immediate Release

Chicago, IL – November 16, 2009 – Zacks.com announces the list of stocks featured in the Analyst Blog. Every day the Zacks Equity Research analysts discuss the latest news and events impacting stocks and the financial markets. Stocks recently featured in the blog include: GlaxoSmithKline plc (GSK), Sanofi-Aventis (SNY), Novartis (NVS), Baxter International (BAX) and AstraZeneca (AZN).

Get the most recent insight from Zacks Equity Research with the free Profit from the Pros newsletter: http://at.zacks.com/?id=5513

Here are highlights from Friday’s Analyst Blog:

Glaxo H1N1 Vaccine Approved

GlaxoSmithKline plc (GSK) recently received approval from the U.S. Food and Drug Administration (FDA) for its unadjuvanted influenza A (H1N1) pandemic vaccine. The FDA approved the supplemental biologics license application (sBLA), which was filed as a strain change supplement to Glaxo’s FluLaval seasonal flu vaccine. This

...

GlaxoSmithKline plc (GSK) recently received approval from the U.S. Food and Drug Administration (FDA) for its unadjuvanted influenza A (H1N1) pandemic vaccine.  The FDA approved the supplemental biologics license application (sBLA), which was filed as a strain change supplement to Glaxo’s FluLaval seasonal flu vaccine. This means that Glaxo can now market its swine flu vaccine for use in adults to prevent influenza.     The company has already received an order for 7.6 million doses of its swine flu vaccine from the United States Department of Health and Human Services. This order is a part of the US Government’s intention to secure about 250 million doses to help fight the swine flu pandemic.   The current outbreak of swine flu pandemic can prove to be a big opportunity for vaccine manufacturers. In addition to Glaxo, other major players in this field include Sanofi-Aventis (SNY), Novartis ...

For Immediate Release

Chicago, IL – November 10, 2009 – Zacks.com announces the latest Industry Outlook. Today, Zacks Equity Research discusses the Big Pharma & Biotech sector, including Alcon (ACL), Novartis (NVS), Gilead Sciences (GILD), Biogen Idec (BIIB) and Acorda Therapeutics (ACOR).

A synopsis of today’s Industry Outlook is presented below. The full article can be read at http://www.zacks.com/stock/news/27081/Big+Pharma+and+Biotech.

In the pharma space, we are positive on stocks like Alcon (ACL) and Novartis (NVS). We believe these companies will continue witnessing revenue growth based on continued international penetration, new product launches and market share expansion. Pipeline expansion through in-licensing deals and acquisitions should also add to growth.

Novartis should see strong vaccine sales this flu season. The company has received approval from the U.S. Food and Drug Administration for its swine flu vaccine, which

...

The pharmaceutical industry has witnessed major changes in 2009. Performance has been affected by factors like sluggish prescription trends, intensifying generic competition and limited phase III catalysts. The next five years are expected to reflect a significant imbalance between new product introductions and patent losses. According to IMS Health (RX), this is the main reason why global pharmaceutical market growth will be restricted to the mid-single digits through 2013. Over the next five years, products that currently generate about $137 billion in sales are expected to face generic competition, including Lipitor, Plavix and Seretide. At the same time, new products are not expected to generate the same level of sales as the products losing patent protection have. With most of the big pharma companies already facing patent challenges for their blockbuster products or likely to face them going forward, the companies have been looking toward mergers ...

Last week, Grupo Aeroportuario del Pacifico, S.A.B. de C.V. (PAC) reported gloomy results for the third quarter ended September 30, 2009. During the quarter, revenues declined 4.8% year over year and reached MXN$40.2 million. The decrease was primarily due to the decrease in aeronautical revenues. Revenues from aeronautical services declined 5.8% and reached MXN$37.8 million, mainly as a result of a decline of MXN$42.4 million in passenger charges, which was offset by an increase in airplane landing fees and airplane parking fees. Non-aeronautical service declined 1.3% to MXN$2.3 million. Cost of services declined 22.4% to MXN$56.1 million; as a percentage of revenues, cost of services decreased 560 basis points. Per workload unit ("WLU"), cost of services declined MXN$6.1 million from MXN$44.3 million in the third quarter of 2008 to MXN$38.2 million in the third quarter of 2009. As a result of the decrease in total ...

Earlier this week, Grupo Aeroportuario del Centro Norte (OMAB) reported encouraging results for the third quarter of 2009.  With the occurrence of swine flu in the Mexico City Airport Terminal 2 Hotel during the quarter, the company took a decisive step in the development of additional sources of non-aeronautical revenues. Total revenues were higher than the three previous quarters, in part as a result of initiatives to preserve aeronautical revenues.  In addition, Grupo Aeroportuario continued to implement cost control measures. These actions contributed to offsetting most of the impact of lower traffic volumes on revenues and to an increase in adjusted EBITDA of 2.6% as compared to the third quarter of 2008, with an adjusted EBITDA margin of 54.0%.  Passenger traffic decreased 15.4% to 3.0 million. Domestic traffic decreased 13.8% and international traffic decreased 25.0%. The suspension of Aviacsa operations since Jul 6, 2009, was ...

The U.S. Airlines industry has gone through several ups and downs in the past five years. Major negative influences on the industry included skyrocketing oil prices since 2005, economic recession in the U.S. since 2008, global economic downturn in 2009 and the "swine flu" outbreak. The airlines industry is cyclical and sensitive to a number of key drivers, the most prominent of which is the world price of crude oil. Since the beginning of 2009, prices of crude oil have been half of what they had been the year before, creating some relief for airlines. However, some industry operators hedged their fuel contracts at higher rates and are still paying the price. Many of the top airlines in the industry have responded by reducing services and aircraft fleet sizes, introducing new fees and higher fuel surcharges and reducing the number of people employed. Even with the price ...

Dr Stock Pick HOT News & Alerts!

_________________________________________

FREE Daily Stock Alerts From DrStockPick.com

_________________________________________

Monday October 26, 2009

DrStockPick.com Stock Report!

PWRM, BCRX

**************************************************************

PWRM, Power 3 Medical Products Inc, PWRM.OB

Power3 Medical Products, Inc. is a leading bio-medical company engaged in the commercialization of neurodegenerative disease and cancer biomarkers, pathways, and mechanisms of diseases through the development of diagnostic tests and drug targets. Power3’s patent-pending technologies are being used to develop screening and diagnostic tests for the early detection and prognosis of disease, identify protein biomarkers, and drug targets. Diagnostic tests are targeted toward markets with critical unmet needs in areas including neurodegenerative disease (NuroPro) and breast cancer (BC-SeraPro). Power3 expects to complete phase II clinical

...

Dr Stock Pick HOT News & Alerts!

_________________________________________

FREE Daily Stock Alerts From DrStockPick.com

_________________________________________

DrStockPick.com Watch List!

My Picks for Monday October 26, 2009, are:

**************************************************************

BCRX, BioCryst Pharmaceuticals, Inc.

U.S. President Barack Obama has declared 2009 H1N1 swine flu a national emergency, the White House said on Saturday.

BCRX designs, optimizes and develops novel small-molecule pharmaceuticals that block key enzymes involved in infectious diseases, cancer and inflammatory diseases. BCRX has progressed two novel compounds into late-stage pivotal clinical trials; peramivir, an anti-viral for influenza, and forodesine, a purine nucleoside phosphorylase (PNP) inhibitor for cutaneous T-cell lymphoma

The U.S. Food and Drug Administration (FDA), in response to a request from the U.S. Centers for Disease Control and Prevention,

...